Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 247 participants.

Also called NCT02924064

  • Study
  • In this atlas

Overview

Design
Interventional study; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 247 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02924064
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02924064. Quadruple masking; primary purpose treatment. Start 2016-09 (registry gives no type); primary completion 2018-09-25 (actual). Results posted on 2022-01-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Teneligliptin 20mg
Intervention (Drug)
Placebo
Intervention (Drug)
Metformin ≥ 1000 mg
Lead sponsor
Tanabe Pharma Corporation (class: industry)

Record details

Record id
cardio:ct-nct02924064
Content hash
22d64ce3abd9ede8d173b1786f6cd2ce5e3892741184c095da270582889851a7